PL2235007T3 - Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny - Google Patents

Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny

Info

Publication number
PL2235007T3
PL2235007T3 PL08866835T PL08866835T PL2235007T3 PL 2235007 T3 PL2235007 T3 PL 2235007T3 PL 08866835 T PL08866835 T PL 08866835T PL 08866835 T PL08866835 T PL 08866835T PL 2235007 T3 PL2235007 T3 PL 2235007T3
Authority
PL
Poland
Prior art keywords
dibenz0
oxepine
receptor antagonists
mineralocorticoid receptor
derived
Prior art date
Application number
PL08866835T
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2235007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2235007T3 publication Critical patent/PL2235007T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08866835T 2007-12-19 2008-12-09 Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny PL2235007T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
EP08866835A EP2235007B1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
PL2235007T3 true PL2235007T3 (pl) 2013-03-29

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08866835T PL2235007T3 (pl) 2007-12-19 2008-12-09 Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny

Country Status (34)

Country Link
US (1) US7994164B2 (pl)
EP (2) EP2235007B1 (pl)
JP (1) JP5562866B2 (pl)
KR (1) KR101254382B1 (pl)
CN (1) CN101903377B (pl)
AR (1) AR069554A1 (pl)
AU (1) AU2008343524B2 (pl)
BR (1) BRPI0820805A2 (pl)
CA (1) CA2710409C (pl)
CL (1) CL2008003600A1 (pl)
CO (1) CO6300953A2 (pl)
DK (1) DK2235007T3 (pl)
DO (1) DOP2010000185A (pl)
EA (1) EA017668B1 (pl)
EC (2) ECSP10010266A (pl)
ES (2) ES2459318T3 (pl)
GT (1) GT201000179A (pl)
HK (1) HK1144284A1 (pl)
HR (1) HRP20120916T1 (pl)
IL (1) IL206353A (pl)
MA (1) MA31910B1 (pl)
MX (1) MX2010006911A (pl)
MY (1) MY150474A (pl)
NZ (1) NZ586300A (pl)
PE (1) PE20091057A1 (pl)
PL (1) PL2235007T3 (pl)
PT (1) PT2235007E (pl)
RS (1) RS52594B (pl)
SI (1) SI2235007T1 (pl)
TN (1) TN2010000292A1 (pl)
TW (1) TWI431010B (pl)
UA (1) UA100131C2 (pl)
WO (1) WO2009085584A1 (pl)
ZA (1) ZA201004257B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
CA2751901C (en) 2009-03-12 2013-08-06 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
WO2011141456A1 (en) 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
EA029518B1 (ru) 2014-06-30 2018-04-30 Астразенека Аб Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
BR112017007112A2 (pt) * 2014-11-21 2017-12-26 Lilly Co Eli compostos de 1,2-benzotiazol para o tratamento de distúrbios renais
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JP7090599B2 (ja) * 2016-09-24 2022-06-24 山東亨利醫藥科技有限責任公司 ミネラルコルチコイド受容体拮抗薬を含む医薬組成物及びその使用
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
CA2361734A1 (en) 1999-01-26 2000-10-12 Andre Rosowsky Pharmaceutically active compounds and methods of use thereof
NZ532827A (en) * 2001-11-21 2007-09-28 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7482344B2 (en) * 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
ES2308296T3 (es) 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
KR101107800B1 (ko) 2006-10-31 2012-01-25 화이자 프로덕츠 인코포레이티드 무기질코르티코이드 수용체 길항제로서의 피라졸린 화합물
CN101652142B (zh) 2007-03-29 2013-01-02 Msd欧斯股份有限公司 盐皮质激素受体拮抗剂
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
EP2252615A1 (en) 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
CA2751901C (en) 2009-03-12 2013-08-06 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
HRP20120916T1 (hr) 2012-12-31
BRPI0820805A2 (pt) 2015-06-16
CA2710409A1 (en) 2009-07-09
US7994164B2 (en) 2011-08-09
JP2011507868A (ja) 2011-03-10
IL206353A0 (en) 2010-12-30
TN2010000292A1 (en) 2011-11-11
ECSP10010266A (es) 2010-07-30
ECSP12012048A (es) 2012-08-31
AR069554A1 (es) 2010-02-03
MY150474A (en) 2014-01-30
PE20091057A1 (es) 2009-07-20
GT201000179A (es) 2012-04-16
NZ586300A (en) 2012-06-29
KR101254382B1 (ko) 2013-04-15
TWI431010B (zh) 2014-03-21
EA201070762A1 (ru) 2010-12-30
EA017668B1 (ru) 2013-02-28
PT2235007E (pt) 2013-01-22
AU2008343524A1 (en) 2009-07-09
US20090163472A1 (en) 2009-06-25
SI2235007T1 (sl) 2013-01-31
CA2710409C (en) 2012-11-06
DOP2010000185A (es) 2010-09-15
EP2235007B1 (en) 2012-10-31
MA31910B1 (fr) 2010-12-01
CN101903377A (zh) 2010-12-01
JP5562866B2 (ja) 2014-07-30
KR20100082866A (ko) 2010-07-20
TW200930721A (en) 2009-07-16
EP2235007A1 (en) 2010-10-06
UA100131C2 (uk) 2012-11-26
ZA201004257B (en) 2011-11-30
RS52594B (en) 2013-04-30
ES2396605T3 (es) 2013-02-22
CN101903377B (zh) 2014-07-09
CL2008003600A1 (es) 2010-02-19
AU2008343524B2 (en) 2012-03-08
EP2537845B1 (en) 2014-03-19
ES2459318T3 (es) 2014-05-09
DK2235007T3 (da) 2012-12-17
MX2010006911A (es) 2010-10-05
CO6300953A2 (es) 2011-07-21
IL206353A (en) 2014-06-30
HK1144284A1 (en) 2011-02-11
WO2009085584A1 (en) 2009-07-09
EP2537845A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
HK1144284A1 (en) 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
HRP20151108T1 (en) Nogo receptor antagonists
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
EP2349270A4 (en) 2,5-DISUBSTITUTED MORPHOLINE OREXIN RECEPTOR ANTAGONISTS
EP2151236A4 (en) G PROTEIN COUPLED RECEPTOR AGONIST
EP2214676A4 (en) OXININE RECEPTOR ANTAGONISTS SUBSTITUTED DIAZEPAN TYPE
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
IL201165A0 (en) CRIg ANTAGONISTS
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
GB0717233D0 (en) Traffic monitoring
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
PL1912976T3 (pl) Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a
EP2153736A4 (en) NEW LEUKOTRIEN RECEPTOR ANTAGONIST
IL207700A0 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists
EP2222676A4 (en) A1-adenosine receptor antagonistic
EP2163557A4 (en) FUNCTIONAL DETECTIVE VITAMIN D RECEPTOR AGONISTS
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
IL211803A0 (en) Quinazoline derivatives as nk3 receptor antagonists
ZA200810564B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
GB0701632D0 (en) MET receptor antagonists